About ZHAOKE OPHTH-B Company

Zhaoke Ophthalmology Co., Ltd. is an ophthalmology pharmaceutical company dedicated to the research, development and commercialization of ophthalmic treatments to meet the huge medical demand gap in China. With deep expertise in the field, we have established a comprehensive ophthalmic drug pipeline with 25 drug candidates through independent development or licensing, covering most major ophthalmic indications affecting the anterior and posterior ocular sections. To prepare for the upcoming product launch, we have also set up an advanced eye medicine manufacturing facility and are in the process of forming an experienced marketing team. Our goal is to become a leader in the Chinese and neighboring ASEAN markets. We are led by an international management team with decades of industry experience and track record in R&D, clinical operations, manufacturing, regulatory communications, business development, and commercialization of ophthalmic therapies. We have established an ophthalmic drug pipeline composed of 13 innovative drugs and 12 generic drugs (classified according to the National Drug Administration's “Administrative Measures on Drug Registration”). Eight drug candidates in our innovative pipeline have the potential to become leading products in the Chinese market if approved. Our generic drug pipeline includes six potential first-generation drugs in China, which we believe will bring us immediate cash flow and a significant first-mover advantage in commercial-scale manufacturing and marketing. According to insightful data, we have one of the most comprehensive ophthalmic drug pipelines in China. In designing our pipeline, we initially focused our strategy on China's top five ophthalmic indications (in terms of market potential), including dry eye, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. Through this product pipeline strategy, we strive to provide an indispensable one-stop solution. We have developed in-house capabilities in key areas of ophthalmic drug development. Our dedicated in-house R&D, clinical and regulatory capabilities enable us to simultaneously advance multiple innovative and generic drug candidates through pre-clinical and clinical stages. We have a strong track record in business development and have been approved by international partners to introduce a variety of drug candidates with high growth potential and for key indications. To differentiate ourselves from our Chinese competitors, we have set up a commercial-scale advanced production facility designed and built according to Chinese, American and EU cGMP standards to produce ophthalmic drugs. We are also in the process of forming an experienced commercial team with extensive experience covering various national sales channels in China and in dealing with ophthalmologists. We believe that these sophisticated capabilities will help us bring innovative, comprehensive eye treatments to the market and become the partner of choice for multinational pharmaceutical companies.